43 reports

  • RISK FACTORS AND COMORBIDITIES FOR PROSTATE CANCER
  • ETHNICITY

BAY-##, AN ORAL ATR INHIBITOR, IS BEING INVESTIGATED IN A PHASE I STUDY (BAYER, NCT##) IN SOLID TUMORS (INCLUDING PCA) AND LYMPHOMAS.

  • Prostate Cancer
  • East Asia
  • United States
  • Forecast
  • Pfizer Inc.
  • Ethnicity
  • 3.2 RISK FACTORS AND COMORBIDITIES

National Cancer Institute, 2019b Ethnicity TABLE ##: RISK FACTORS AND COMORBIDITIES FOR PROSTATE CANCER Prior malignancies Prior malignancies and current cancers, such as lymphoma, leukemia, and metastatic cancers, are often observed in men with prostate cancer.

  • Cancer
  • Prostate Cancer
  • Japan
  • United States
  • Forecast

MARKET ##.

  • Prostate Cancer
  • Canada
  • Europe
  • United States
  • World
  • PRESENTS KNOWN RISK FACTORS AND COMORBIDITIES FOR PCA.
  • Ethnicity

ASTELLAS, A DOSE ESCALATION AND EXPANSION STUDY OF ASP## TO SUBJECTS WITH ADVANCED REFRACTORY TUMORS AND LYMPHOMA, NCT##.

  • Hospital
  • Prostate Cancer
  • United States
  • Forecast
  • PROVENGE group

Various types of cancer include skin, breast, colorectal, lung, lymphoma, and prostate cancers.

  • Prostate Cancer
  • World
  • C.R. Bard, Inc.
  • MDxHealth SA
  • SOMATEX MEDICAL TECHNOLOGIES GMBH
  • A) PIPELINE BY MOA

PLOS ONE; ##: ##-##.

  • Prostate Cancer
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Pfizer Inc.
  • 3.2 RISK FACTORS AND COMORBIDITIES
  • PRESENTS KNOWN RISK FACTORS AND COMORBIDITIES FOR PROSTATE CANCER.

Prior malignancies and current cancers, such as lymphoma, leukemias, and metastatic cancers, are often observed in men with prostate cancer.

  • Prostate Cancer
  • Japan
  • United Kingdom
  • United States
  • Forecast
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H1 2016
  • DORMANT PROJECTS (CONTD..1), H1 2016

Regulator Bcl-X or Protein Phosphatase ## Regulatory Bcl-##-Like Protein ## (Bcl-xl or Bcl##-L-## or Apoptosis Subunit ## or B-cell Lymphoma Extra Large) - Pipeline Review, H## 2016 Reference Code: GMDHC##TDB Publication Date: June 2016 Introduction GLOBAL MARKETS DIR

  • Chemotherapy
  • Prostate Cancer
  • Therapy
  • United States
  • Product Initiative

One or both tests may be directed at breast or lung cancer, lymphoma, or melanoma tumors, and up to one test can be used for transplant, chronic obstructive pulmonary disease, or immunology/ autoimmunity disorders.

  • Prostate Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

One or both tests may be directed at breast or lung cancer, lymphoma, or melanoma tumors, and up to one test can be used for transplant, chronic obstructive pulmonary disease, or immunology/ autoimmunity disorders.

  • Prostate Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

MARKET ##.

  • Prostate Cancer
  • Canada
  • Europe
  • United States
  • World
  • DORMANT PRODUCTS, H1 2019
  • DORMANT PRODUCTS, H1 2019 (CONTD..1), H1 2019

As of October 2014, it was in Phase I stage for advanced solid tumors and lymphomas as first line of therapy.

  • Prostate Cancer
  • United States
  • World
  • Company
  • Product Initiative
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H1 2019
  • DORMANT PRODUCTS, H1 2019 (CONTD..1), H1 2019

By using E mu-Myc lymphoma cells lacking p##, it was showed that CR mimetics such as ##-deoxyglucose led to a decrease in Mcl-## expression and sensitized lymphoma cells to ABT-##-induced death independently of p##.

  • Prostate Cancer
  • Therapy
  • United States
  • Product Initiative
  • AbbVie Inc.
  • 2.2 United States - Liquid Biopsy Screening Potential Market
  • United States - Liquid Biopsy Potential Market (Million US$), 2015 - 2020

Liquid Biopsy Market - Major Deals Analysis ##.

  • Prostate Cancer
  • North America
  • United States
  • Forecast
  • Biocept, Inc.

This may be particularly true with trying to make a diagnosis of lymphoma.

  • Biopsy
  • Cancer
  • Prostate Cancer
  • United States
  • Forecast
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2018
  • Non-Small Cell Lung Cancer

By using E mu-Myc lymphoma cells lacking p##, it was showed that CR mimetics such as ##-deoxyglucose led to a decrease in Mcl-## expression and sensitized lymphoma cells to ABT-##-induced death independently of p##.

  • Prostate Cancer
  • Therapy
  • United States
  • World
  • AbbVie Inc.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ##, ## and ## respectively.

  • Cancer
  • Prostate Cancer
  • United States
  • Product Initiative
  • Genentech, Inc.
  • Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
  • Products under Development by Companies, H1 2018

Five patients had an objective response; ## CRs (## Tcell/ histocyte-rich DLBCL, ## ABC-DLBCL), ## PRs (## follicular lymphoma, ## ABC-DLBCL) and ## patients had prolonged (greater than ## months) SD.

  • Leukemia
  • Prostate Cancer
  • World
  • Product Initiative
  • Forma Publishing Group

Korfin oversaw the market access strategy, including payer relations and reimbursement, for Yescarta, the first approved CAR-T therapy in lymphoma.

  • Pharmaceutical
  • Prostate Cancer
  • United States
  • Company
  • Tyme Technologies, Inc
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2018

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Prostate Cancer
  • Targeted Therapy
  • World
  • Product Initiative
  • IMMD
  • There Is Limited Phase III Development, but Extensive Phase I-II Trial Activity for Cancer Vaccines in Blood and Prostate Cancers

NCCN Guidelines: B-Cell Lymphomas.

  • Breast Cancer
  • Epidemiology
  • Prostate Cancer
  • Therapy
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cancer
  • Clinical Trial
  • Prostate Cancer
  • World
  • Product Initiative

The company' s product Velcade is used for the treatment of multiple myeloma and relapsed mantle cell lymphoma.

  • Hormone
  • Prostate Cancer
  • United States
  • Product Initiative
  • Janssen Biotech, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H1 2018

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Brain Cancer
  • Prostate Cancer
  • World
  • Product Initiative
  • IMMD
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Chemotherapy
  • Hormone
  • Prostate Cancer
  • United States
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Chemotherapy
  • Clinical Trial
  • Hormone
  • Prostate Cancer
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Drug Development
  • Prostate Cancer
  • Therapy
  • World
  • Product Initiative
  • GS-5829 - DRUG PROFILE
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

IT IS ALSO IN PHASE I/ II STAGE OF DEVELOPMENT FOR THE TREATMENT OF B-CELL LYMPHOMAS SUCH AS FOLLICULAR LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA, B-CELL HODGKIN LYMPHOMA AND B-CELL CHRONIC LYMPHOCYTIC L

  • Oncology
  • Prostate Cancer
  • United States
  • Company
  • Product Initiative

Summary Exiqon A/S (Exiqon), a subsidiary of Qiagen NV is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company’s product categories include microRNA research, incRNA research, mRNA research, DNA research, custom oligos and other reagent products. Its microRNA research products...

  • Cancer
  • Pathology
  • Prostate Cancer
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Oncology
  • Prostate Cancer
  • World
  • Product Initiative
  • Novartis AG